Shares of IRIDEX Corporation (NASDAQ: IRIX) traded lower ahead of the company’s third-quarter 2026 earnings call scheduled for November 17. The stock was recently quoted at $0.6878, down 0.32% from its previous close of $0.6900, while the pre-market indication stood at $0.6800, representing a decline of 1.13%.
The ophthalmic medical technology company develops laser-based systems, delivery devices, and consumable instruments used to treat sight-threatening eye diseases. Investors are approaching the earnings announcement with attention on the company’s financial performance and developments across its medical device portfolio.
Stock Performance and Market Data
IRIDEX had an intraday market capitalization of approximately $12.08 million. Its trading volume reached 84,563 shares, below the reported average volume of 388,759 shares. Over the five-day period shown, the stock declined approximately 3.13%.
The company recorded a 52-week trading range of $0.61 to $1.65, while its five-year monthly beta stood at 0.63. Earnings per share (TTM) were reported at negative $0.20, with no trailing price-to-earnings ratio available.
The displayed one-year analyst price target was $2.75, and the platform’s rating was Neutral. These figures provide market reference points but do not establish a forecast of future performance.
Business Overview and Medical Technology Portfolio
Headquartered in Mountain View, California, IRIDEX develops ophthalmic laser systems and related medical devices for the treatment of glaucoma and retinal disorders. Its products are used by ophthalmologists, hospitals, research and teaching institutions, surgical centers, veterinary practices, and office-based clinics.
Its glaucoma portfolio includes Cyclo G6 laser systems and IQ 532 and IQ 577 laser systems. For retinal conditions, the company offers products such as OcuLight TX, OcuLight SLx, OcuLight SL, and OcuLight GL, which are used in photocoagulation procedures addressing conditions including proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
The company also provides delivery devices and specialized instruments, including the slit lamp adapter, TxCell scanning laser delivery system, MicroPulse P3 Probe, G-Probe, G-Probe Illuminating, and EndoProbe family of products. These technologies support various ophthalmic procedures, including transscleral laser therapy and treatment of glaucoma.
IRIDEX distributes its products through direct and independent sales channels in the United States and independent distributors internationally. Its commercial reach includes markets across Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
Q3 2026 Earnings Call and Upcoming Events
IRIDEX scheduled its third-quarter 2026 earnings call for November 17 at 5:00 p.m. Eastern Time. The earnings date is also listed as November 17, 2026.
The upcoming announcement will provide investors with an opportunity to assess the company’s operating performance and financial position. The supplied information does not include preliminary quarterly revenue, earnings expectations, or management guidance.
Closing Insights
IRIDEX enters its Q3 2026 earnings announcement with shares trading below $1 and market capitalization of approximately $12.08 million. Its specialized ophthalmic technology portfolio provides exposure to the medical device market, particularly laser-based treatments for glaucoma and retinal diseases.
Investor attention will focus on quarterly financial results, operating performance, and management commentary regarding the company’s commercial position. Revenue trends, profitability, cash resources, and demand for its ophthalmic products will be important factors to monitor as the company moves into the remainder of 2026.